Today's the day! Be sure to take in PD Dr. Rudi Pistulli's presentation on the #Corvia #atrialshunt. Trust us, you won't want to miss it! #HFpEF #cardiotwitter #CSI #CSIFocusDHF #CSIDHF
Corvia Medical, Inc.
Medical Equipment Manufacturing
Tewksbury, MA 2,600 followers
Corvia Medical is revolutionizing the treatment of heart failure (HF) with a novel transcatheter structural heart device
About us
Corvia Medical, Inc. is revolutionizing the treatment of heart failure with a novel transcatheter structural heart device. Founded in 2009 and headquartered in Tewksbury, MA, Corvia Medical is dedicated to transforming the standard of care for heart failure treatment, enabling patients to reclaim their lives. The Corvia® Atrial Shunt is the world’s first transcatheter device approved by the European Union to treat heart failure with preserved (HFpEF) or mid-range (HFmrEF) ejection fraction. Privately held, the company is backed by Third Rock Ventures, General Catalyst Partners, AccelMed, and Lumira Ventures, Edward Lifesciences and an undisclosed strategic investor. In the United States, the Corvia Atrial Shunt System is an investigational device and not available for commercial distribution or sale.
- Website
-
http://www.corviamedical.com
External link for Corvia Medical, Inc.
- Industry
- Medical Equipment Manufacturing
- Company size
- 11-50 employees
- Headquarters
- Tewksbury, MA
- Type
- Privately Held
- Founded
- 2009
- Specialties
- medical device, hfpef, hfref, heart failure, congestive heart failure, interventional cardiology, structural heart, heart failure with preserved ejection fraction, heart failure with reduced ejection fraction, and hfmref
Locations
-
Primary
Get directions
One Highwood Drive
300
Tewksbury, MA 01876, US
Employees at Corvia Medical, Inc.
Updates
-
Attending #CSIFocusDHF? Please join us to learn about the latest evidence behind atrial shunting! #atrialshunt #HFpEF #Corvia #cardiotwitter #CSI #CSIDHF
-
-
There may be hope for #HFpEF patients. Prof. Gustafsson shares his thoughts on REDUCE LAP-HF Responders. Learn more: https://lnkd.in/ezJEd4tA Consider referring patients to the #RESPONDERHF study today: https://lnkd.in/djAxwFFx #clinicaltrials #hfpef #heartfailure #hearthealth #innovativetherapy #innovativetreatment #cardiotwitter #atrialshunt
-
The world of #atrialshunt therapy for #hfpef is quickly evolving with the #RESPONDERHF trial. Learn more about the trial and new options for #heartfailure patients: https://lnkd.in/djAxwFFx #clinicaltrials #heartfailure #hearthealth #innovativetherapy #innovativetreatment #cardiotwitter
-
-
REDUCE LAP-HF II Data: Interested in #HFpEF? Prof. Cikes explains patient phenotyping in REDUCE LAP-HF responders. Learn more: https://lnkd.in/ezJEd4tA Consider referring patients to the #RESPONDERHF study today: https://lnkd.in/djAxwFFx
-
The REDUCE LAP-HF II study identified a novel 'Responder Group' of #HFpEF patients positively responsive to the Corvia #atrialshunt. This group is now being studied in #RESPONDERHF – consider referring patients to the study today: https://lnkd.in/djAxwFFx #clinicaltrials #heartfailure #hearthealth #hfpef #innovativetherapy #innovativetreatment #cardiotwitter
-
-
Corvia Medical, Inc. reposted this
-
Recently published data support the durability of the Corvia #atrialshunt: 98% of implanted shunts remained patent 2 years after implant. Learn more: https://lnkd.in/ezJEd4tA Consider referring patients to the #RESPONDERHF study today: https://lnkd.in/djAxwFFx #clinicaltrials #heartfailure #hearthealth #hfpef #innovativetherapy #innovativetreatment #cardiotwitter
-
-
Building on our strong 2-year results, the recently published 3-year clinical outcomes for the REDUCE LAP-HF II responder group confirm the safety and efficacy of the Corvia #atrialshunt. #HFpEF #clinicaltrials #heartfailure #innovativetherapy #innovativetreatment #cardiotwitter #hearthealth https://lnkd.in/eKqy9NXW
Corvia Medical Announces Three-Year Clinical Trial Results Confirming Significant and Durable Benefits of the Corvia Atrial Shunt in Heart Failure Patients - Corvia Medical
https://us.corviamedical.com
-
2 years after implant, #HFpEF Responder Group patients with the Corvia #atrialshunt saw a 46% greater improvement in their quality of life vs. control, as measured by KCCQ. Learn more: https://lnkd.in/ezJEd4tA Consider referring patients to the #RESPONDER-HF study today: https://lnkd.in/djAxwFFx #clinicaltrials #heartfailure #hearthealth #innovativetherapy #innovativetreatment #cardiotwitter
-